Tumour necrosis factor a as a therapeutic target for immune-mediated inflammatory diseases

被引：42

作者：

Taylor, PC ^{[1
]}

Williams, RO ^{[1
]}

Feldmann, M ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Kennedy Inst, Div Rheumatol, Fac Med, London W68LH, England

来源：

CURRENT OPINION IN BIOTECHNOLOGY | 2004年 / 15卷 / 06期

关键词：

D O I：

10.1016/j.copbio.2004.09.005

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Preclinical studies have identified and validated tumour necrosis factor alpha (TNFalpha) as a key disease molecule and therapeutic target for immunotherapeutic intervention in many immune-mediated inflammatory diseases. Clinical indications include rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriasis. Recent clinical findings indicate that many chronic inflammatory disorders share certain pathogenic pathways, whereas others are limited to particular disease phenotypes. Better understanding of these pathogenic pathways will inform the development of new therapeutic approaches leading to more complete and sustained disease remissions.

引用

页码：557 / 563

页数：7

共 79 条

[41] Anti-cytokine therapy for rheumatoid arthritis [J].

Maini, RN ;

Taylor, PC .

ANNUAL REVIEW OF MEDICINE, 2000, 51 :207-229

[42]

Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO

[43]

2-W

[44] Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate [J].

Maini, RN ;

Breedveld, FC ;

Kalden, JR ;

Smolen, JS ;

Furst, D ;

Weisman, MH ;

St Clair, EW ;

Keenan, GF ;

van der Heijde, D ;

Marsters, PA ;

Lipsky, PE .

ARTHRITIS AND RHEUMATISM, 2004, 50 (04) :1051-1065

[45] Targeted anticytokine therapy in patients with chronic heart failure - Results of the Randomized Etanercept Worldwide evALuation (RENEWAL) [J].

Mann, DL ;

McMurray, JJV ;

Packer, M ;

Swedberg, K ;

Borer, JS ;

Colucci, WS ;

Djian, J ;

Drexler, H ;

Feldman, A ;

Kober, L ;

Krum, H ;

Liu, P ;

Nieminen, M ;

Tavazzi, L ;

van Veldhuisen, DJ ;

Waldenstrom, A ;

Warren, M ;

Westheim, A ;

Zannad, F ;

Fleming, T .

CIRCULATION, 2004, 109 (13) :1594-1602

[46] Inefficacy of infliximab in primary Sjogren's syndrome -: Results of the randomized, controlled trial of Remicade in primary Sjogren's syndrome (TRIPSS) [J].

Mariette, X ;

Ravaud, P ;

Steinfeld, S ;

Baron, G ;

Goetz, J ;

Hachulla, E ;

Combe, B ;

Puéchal, X ;

Pennec, Y ;

Sauvezie, B ;

Perdriger, A ;

Hayem, G ;

Janin, A ;

Sibilia, J .

ARTHRITIS AND RHEUMATISM, 2004, 50 (04) :1270-1276

[47] Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial [J].

Mease, PJ ;

Goffe, BS ;

Metz, J ;

VanderStoep, A ;

Finck, B ;

Burge, DJ .

LANCET, 2000, 356 (9227) :385-390

[48]

Mielants H, 1996, BAILLIERE CLIN RHEUM, V10, P147

[49] LOCATION OF TUMOR-NECROSIS-FACTOR-ALPHA BY IMMUNOHISTOCHEMISTRY IN CHRONIC INFLAMMATORY BOWEL-DISEASE [J].

MURCH, SH ;

BRAEGGER, CP ;

WALKERSMITH, JA ;

MACDONALD, TT .

GUT, 1993, 34 (12) :1705-1709

[50] CYTOKINES IN STOOLS OF CHILDREN WITH INFLAMMATORY BOWEL-DISEASE OR INFECTIVE DIARRHEA [J].

NICHOLLS, S ;

STEPHENS, S ;

BRAEGGER, CP ;

WALKERSMITH, JA ;

MACDONALD, TT .

JOURNAL OF CLINICAL PATHOLOGY, 1993, 46 (08) :757-760

← 1 2 3 4 5 6 7 8 →